Adjuvant Therapy of Jianpi Yishen Xiezhuo Formula (健脾益肾泄浊方) on Residual Renal Function in Patients with Continuous Ambulatory Peritoneal Dialysis of Spleen-kidney Deficiency and Damp-turbidity Syndrome: A Randomized Controlled Trial
ZHAO Jing,ZHAO Wenjing,CAI Zhen,et al.Adjuvant Therapy of Jianpi Yishen Xiezhuo Formula (健脾益肾泄浊方) on Residual Renal Function in Patients with Continuous Ambulatory Peritoneal Dialysis of Spleen-kidney Deficiency and Damp-turbidity Syndrome: A Randomized Controlled Trial[J].Journal of Traditional Chinese Medicine,2023,64(16):1656-1660.
ZHAO Jing,ZHAO Wenjing,CAI Zhen,et al.Adjuvant Therapy of Jianpi Yishen Xiezhuo Formula (健脾益肾泄浊方) on Residual Renal Function in Patients with Continuous Ambulatory Peritoneal Dialysis of Spleen-kidney Deficiency and Damp-turbidity Syndrome: A Randomized Controlled Trial[J].Journal of Traditional Chinese Medicine,2023,64(16):1656-1660.DOI: 10.13288/j.11-2166/r.2023.16.008.
(健脾益肾泄浊方, JYXF) on residual renal function (RRF) in patients with continuous ambulatory peritoneal dialysis (CAPD) of spleen-kidney deficiency and damp-turbidity syndrome.
Methods
2
Seventy CAPD patients with spleen-kidney deficiency and damp-turbidity syndrome were randomly divided into treatment group and control group, 35 cases each. The control group was treated with CAPD plus basic treatment, while the treatment group was given JYXF once a day additionally. The course of treatment in both groups was 24 weeks. RRF before and at 12- and 24-week treatment, urine volume decline rate at 12- and 24-week treatment were compared between groups, and the safety was observed.
Results
2
The RRF of the treatment group was significantly higher than that of the control group at 12 weeks (2.55 ml/min, [1.71, 3.9]
vs
1.65 ml/min, [0.72, 2.65] and at 24 weeks (2.40 ml/min, [1.41, 3.41]
vs
1.33 ml/min, [0.63, 2.69],
P
<0.05). After treatment, RRF in the control group decreased significantly at 12 and 24 weeks, while RRF in the treatment group decreased significantly at 24 weeks (
P
<0.05). The decline rate of urine volume in the treatment group was lower than that in the control group at 24 weeks (
P
<0.05). During the treatment, one case of hyperkalemia occurred in the control group, and there was no adverse events in the treatment group.
Conclusion
2
The adjuvant therapy of JYXF can delay the RRF decline in CAPD patients of spleen-kidney deficiency and damp-turbidity syndrome, and has a protective effect on RRF.
CADNAPAPHORNCHAI MA , TEITELBAUM I . Strategies for the preservation of residual renal function in pediatric dialysis patients [J]. Pediatr Nephrol , 2014 , 29 ( 5 ): 825 - 836 .
ANDDRASSY KM . Comments on ‘KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease’ [J]. Kidney Int , 2013 , 84 ( 3 ): 622 - 623 .